TIDES: Oligonucleotide and Peptide Therapeutics is part of the Informa Connect Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Dr. Kevin Fitzgerald, Ph.D. serves as Head of Research and Senior Vice President at Alnylam
Pharmaceuticals, Inc. and served as its Vice President of Research. Dr. Fitzgerald joined Alnylam in
2005 as an Associate Director of Research and served in roles of increasing responsibility and
leadership since that time. His achievements at Alnylam include leadership of RNAi delivery efforts,
which ... resulted two clinically validated modes of siRNA delivery. He led multiple programs –
including Alnylam’s PCSK9 program – from discovery through pre-clinical development, regulatory
submissions and early clinical development. He was a Senior Research Scientist and Group Leader at
Bristol Myers Squibb, where Dr. Fitzgerald contributed to the development of multiple
pharmaceutical products and managed several technology and drug development alliances. He was
a Lead Author and Co-author on Alnylam’s seminal papers in The Lancet and the New England
Journal of Medicine, which demonstrated the effects of RNAi therapeutics in man. He has B.S. in
Genetics from Cornell University and Ph.D. in Molecular Biology from Princeton University. He
completed his Post-Doctoral Fellowship in Oncology at Harvard Medical School.